Moderna, Inc. — MRNA
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $54.26 | $21.52B | - | -11.7 | N/A | - | - | 2.5 |
Latest Headlines
- · Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
- · 3 Unpopular Stocks We Approach with Caution
- · OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
- · Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors
- · 3 Mid-Cap Stocks We’re Skeptical Of
- · Moderna eyes international markets as growth driver, says Bank of America
Revenue & Net Income
| Date | Revenue | Net_Income | EPS | Last_Updated | Revenue_Change | Net_Income_Change | EPS_Change | |
|---|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $274M | $-747M | $-1.96 | 2024-02-03 03:17:10 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $18,875M | $8,362M | $30.31 | 2026-04-15 21:57:08 | 6788.7% | -1219.4% | -1646.4% |
| 2 | 2022-12-31 | $18,875M | $8,362M | $21.26 | 2026-04-15 21:57:08 | 0.0% | 0.0% | -29.9% |
| 3 | 2023-12-31 | $6,754M | $-4,714M | $-12.33 | 2026-04-15 21:57:08 | -64.2% | -156.4% | -158.0% |
| 4 | 2024-12-31 | $3,199M | $-3,561M | $-9.28 | 2026-04-15 21:57:08 | -52.6% | -24.5% | -24.7% |
| 5 | 2025-12-31 | $1,922M | $-2,822M | $-9.28 | 2026-04-15 21:57:08 | -39.9% | -20.8% | 0.0% |
| 6 | TTM 2025-12-31 | $1,922M | $-2,822M | $-7.26 | 2026-02-17 08:42:53 | 0.0% | 0.0% | -21.8% |
EPS
Forecasts
Y/Y % Change
MRNA Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | Average | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 6788.7% | 0.0% | -64.2% | -52.6% | -39.9% | 8.2% | 34.6% | 953.5% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 | |
| EPS Growth (%) | -1219.4% | 0.0% | -156.4% | -24.5% | -20.8% | -1.5% | -38.1% | -208.7% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 10 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|
| 2022 | $18.9B | $5.1B | $3.3B | $1.1B | $348.0M |
| 2023 | $6.8B | $4.1B | $4.8B | $1.5B | $621.0M |
| 2024 | $3.2B | $1.3B | $4.5B | $1.2B | $189.0M |
| 2025 | $1.9B | $653.0M | $3.1B | $1.0B | $215.0M |
| TTM | $1.9B | $653.0M | $3.1B | $1.0B | $215.0M |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2023 | -64.22 | -19.65 | 47.04 | 36.84 | 78.45 |
| 2024 | -52.64 | -68.69 | -6.23 | -24.21 | -69.57 |
| 2025 | -39.92 | -48.78 | -31.06 | -13.29 | 13.76 |
| TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $12,135M |
| 1 | Cash | $1,132M |
| 2 | Total Liabilities | $2,805M |
| 3 | Total Debt | $734M |
| 4 | Total Equity | $9,330M |
| 5 | Debt to Equity Ratio | 0.08 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $54.26 | 4.3% | Nicks Growth: 8% Nick's Expected Margin: 10% FINVIZ Growth: 26% |
Nicks: 14 Finviz: 72 |
Nick's: 1.441 | 11.2 | - |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $4.85 Revenue | TTM | $6.98 | -87.1% | $35.02 | -35.5% |
| $5.24 Revenue | 2026 | $7.56 | -86.1% | $37.90 | -30.2% |
| $7.06 Revenue | 2027 | $10.17 | -81.3% | $51.02 | -6.0% |
Implied Growth
No implied growth data available.